LYEL
Lyell Immunopharma, Inc.
$14.04
-0.01 (-0.07%)
At close · Jul 6
Market Cap
$327.61M
Shares
23,334,087
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lynn Seely | CEO | $4,222,265 |
| Stephen Hill | COO | $2,076,439 |
| Gary Lee | — | $1,942,621 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Matthew Lang | — | $1,869,632 |
| Lynn Seely | CEO | $1,495,376 |
| Stephen Hill | COO | $1,342,842 |
| Gary Lee | — | $1,309,478 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Charles Newton | CFO | $4,317,424 |
| Matthew Lang | — | $4,008,353 |
| Stephen Hill | COO | $3,108,128 |
| Lynn Seely | CEO | $2,647,476 |
| Tina Albertson | — | $2,391,403 |
| Gary Lee | — | $2,226,356 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lynn Seely | CEO | $18,686,189 |
| Elizabeth Homans | CEO | $12,119,604 |
| Gary Lee | — | $4,128,472 |
| Stephen Hill | COO | $4,068,026 |
| Rahsaan W. Thompson | — | $3,924,659 |
| Charles Newton | CFO | $3,875,468 |
| Matthew Lang | — | — |
| Tina Albertson | — | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Richard Klausner | Chairman | $33,366,629 |
| Charles Newton | CFO | $20,124,792 |
| Elizabeth Homans | CEO | $18,643,569 |
| Stephen Hill | COO | $2,251,930 |
| Matthew Lang | — | — |
| Rahsaan W. Thompson | — | — |
| Lynn Seely | CEO | — |
| Tina Albertson | — | — |
| Gary Lee | — | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Richard Klausner | Chairman | $38,852,236 |
| Elizabeth Homans | CEO | $18,869,275 |
| Stephen Hill | COO | $2,861,732 |
| Lynn Seely | CEO | — |
| Rahsaan W. Thompson | — | — |
| Gary Lee | — | — |
| Charles Newton | CFO | — |